ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.